@article{GoebelPankratzAsaridouetal.2016,
  author    = {G{\"o}bel, Kerstin and Pankratz, Susann and Asaridou, Chloi-Magdalini and Herrmann, Alexander M. and Bittner, Stefan and Merker, Monika and Ruck, Tobias and Glumm, Sarah and Langhauser, Friederike and Kraft, Peter and Krug, Thorsten F. and Breuer, Johanna and Herold, Martin and Gross, Catharina C. and Beckmann, Denise and Korb-Pap, Adelheid and Schuhmann, Michael K. and Kuerten, Stefanie and Mitroulis, Ioannis and Ruppert, Clemens and Nolte, Marc W. and Panousis, Con and Klotz, Luisa and Kehrel, Beate and Korn, Thomas and Langer, Harald F. and Pap, Thomas and Nieswandt, Bernhard and Wiendl, Heinz and Chavakis, Triantafyllos and Kleinschnitz, Christoph and Meuth, Sven G.},
  title     = {Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells},
  series = {Nature Communications},
  volume    = {7},
  journal   = {Nature Communications},
  number    = {11626},
  doi       = {10.1038/ncomms11626},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-165503},
  year      = {2016},
  abstract  = {Aberrant immune responses represent the underlying cause of central nervous system (CNS) autoimmunity, including multiple sclerosis (MS). Recent evidence implicated the crosstalk between coagulation and immunity in CNS autoimmunity. Here we identify coagulation factor XII (FXII), the initiator of the intrinsic coagulation cascade and the kallikrein-kinin system, as a specific immune cell modulator. High levels of FXII activity are present in the plasma of MS patients during relapse. Deficiency or pharmacologic blockade of FXII renders mice less susceptible to experimental autoimmune encephalomyelitis (a model of MS) and is accompanied by reduced numbers of interleukin-17A-producing T cells. Immune activation by FXII is mediated by dendritic cells in a CD87-dependent manner and involves alterations in intracellular cyclic AMP formation. Our study demonstrates that a member of the plasmatic coagulation cascade is a key mediator of autoimmunity. FXII inhibition may provide a strategy to combat MS and other immune-related disorders.},
  language  = {en}
}
@article{BreuerMattheisenFranketal.2018,
  author    = {Breuer, Ren{\´e} and Mattheisen, Manuel and Frank, Josef and Krumm, Bertram and Treutlein, Jens and Kassem, Layla and Strohmaier, Jana and Herms, Stefan and M{\"u}hleisen, Thomas W. and Degenhardt, Franziska and Cichon, Sven and N{\"o}then, Markus M. and Karypis, George and Kelsoe, John and Greenwood, Tiffany and Nievergelt, Caroline and Shilling, Paul and Shekhtman, Tatyana and Edenberg, Howard and Craig, David and Szelinger, Szabolcs and Nurnberger, John and Gershon, Elliot and Alliey-Rodriguez, Ney and Zandi, Peter and Goes, Fernando and Schork, Nicholas and Smith, Erin and Koller, Daniel and Zhang, Peng and Badner, Judith and Berrettini, Wade and Bloss, Cinnamon and Byerley, William and Coryell, William and Foroud, Tatiana and Guo, Yirin and Hipolito, Maria and Keating, Brendan and Lawson, William and Liu, Chunyu and Mahon, Pamela and McInnis, Melvin and Murray, Sarah and Nwulia, Evaristus and Potash, James and Rice, John and Scheftner, William and Z{\"o}llner, Sebastian and McMahon, Francis J. and Rietschel, Marcella and Schulze, Thomas G.},
  title     = {Detecting significant genotype-phenotype association rules in bipolar disorder: market research meets complex genetics},
  series = {International Journal of Bipolar Disorders},
  volume    = {6},
  journal   = {International Journal of Bipolar Disorders},
  doi       = {10.1186/s40345-018-0132-x},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-220509},
  year      = {2018},
  abstract  = {Background Disentangling the etiology of common, complex diseases is a major challenge in genetic research. For bipolar disorder (BD), several genome-wide association studies (GWAS) have been performed. Similar to other complex disorders, major breakthroughs in explaining the high heritability of BD through GWAS have remained elusive. To overcome this dilemma, genetic research into BD, has embraced a variety of strategies such as the formation of large consortia to increase sample size and sequencing approaches. Here we advocate a complementary approach making use of already existing GWAS data: a novel data mining procedure to identify yet undetected genotype-phenotype relationships. We adapted association rule mining, a data mining technique traditionally used in retail market research, to identify frequent and characteristic genotype patterns showing strong associations to phenotype clusters. We applied this strategy to three independent GWAS datasets from 2835 phenotypically characterized patients with BD. In a discovery step, 20,882 candidate association rules were extracted. Results Two of these rules—one associated with eating disorder and the other with anxiety—remained significant in an independent dataset after robust correction for multiple testing. Both showed considerable effect sizes (odds ratio ~ 3.4 and 3.0, respectively) and support previously reported molecular biological findings. Conclusion Our approach detected novel specific genotype-phenotype relationships in BD that were missed by standard analyses like GWAS. While we developed and applied our method within the context of BD gene discovery, it may facilitate identifying highly specific genotype-phenotype relationships in subsets of genome-wide data sets of other complex phenotype with similar epidemiological properties and challenges to gene discovery efforts.},
  language  = {en}
}
@article{BleilevensSoppertHoffmannetal.2021,
  author    = {Bleilevens, Christian and Soppert, Josefin and Hoffmann, Adrian and Breuer, Thomas and Bernhagen, J{\"u}rgen and Martin, Lukas and Stiehler, Lara and Marx, Gernot and Dreher, Michael and Stoppe, Christian and Simon, Tim-Philipp},
  title     = {Macrophage migration inhibitory factor (MIF) plasma concentration in critically ill COVID-19 patients: a prospective observational study},
  series = {Diagnostics},
  volume    = {11},
  journal   = {Diagnostics},
  number    = {2},
  issn      = {2075-4418},
  doi       = {10.3390/diagnostics11020332},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-228967},
  year      = {2021},
  abstract  = {Mortality in critically ill coronavirus disease 2019 (COVID-19) patients is high and pharmacological treatment strategies remain limited. Early-stage predictive biomarkers are needed to identify patients with a high risk of severe clinical courses and to stratify treatment strategies. Macrophage migration inhibitory factor (MIF) was previously described as a potential predictor for the outcome of critically ill patients and for acute respiratory distress syndrome (ARDS), a hallmark of severe COVID-19 disease. This prospective observational study evaluates the predictive potential of MIF for the clinical outcome after severe COVID-19 infection. Plasma MIF concentrations were measured in 36 mechanically ventilated COVID-19 patients over three days after intensive care unit (ICU) admission. Increased compared to decreased MIF was significantly associated with aggravated organ function and a significantly lower 28-day survival (sequential organ failure assessment (SOFA) score; 8.2 ± 4.5 to 14.3 ± 3, p = 0.009 vs. 8.9 ± 1.9 to 12 ± 2, p = 0.296; survival: 56\% vs. 93\%; p = 0.003). Arterial hypertension was the predominant comorbidity in 85\% of patients with increasing MIF concentrations (vs. decreasing MIF: 39\%; p = 0.015). Without reaching significance, more patients with decreasing MIF were able to improve their ARDS status (p = 0.142). The identified association between an early MIF response, aggravation of organ function and 28-day survival may open future perspectives for biomarker-based diagnostic approaches for ICU management of COVID-19 patients.},
  language  = {en}
}